查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070504

品牌學名藥市場規模、佔有率、成長率、全球產業分析、區域趨勢及2026年至2034年預測

Branded Generics Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

品牌非專利藥市場成長要素

全球品牌仿製非專利市場在2025年達到2,043.1億美元，並在2026年至2034年間以6.69%的年複合成長率成長，達到3,660億美元。隨著製藥公司不斷推出非專利藥物的品牌版本，以提高產品知名度、醫生信任度和患者接受度，該市場呈現穩定擴張的態勢。品牌學名藥兼具價格優勢和值得信賴的品牌形象，使其在對價格敏感的醫療保健系統中尤為具有吸引力。

心血管疾病、糖尿病、呼吸系統疾病和神經系統疾病等慢性病的日益普遍，推動了對經濟實惠藥物的需求。Abbott、太陽製藥、瑞迪博士實驗室、西普拉、魯賓和希克瑪製藥等公司不斷透過新產品上市、獲得監管部門批准和建立策略合作夥伴關係，加強其品牌學名藥組合。

市場規模及預測

  • 2025年市場規模：2,043.1億美元
  • 2026年市場規模：2,180.2億美元
  • 2034年市場規模：3,660億美元
  • 年複合成長率（2026-2034年）：6.69%

主要市場趨勢

日益激烈的競爭推動品牌差異化。

影響品牌非專利市場的最重要趨勢之一是對產品差異化的日益重視。隨著越來越多的製造商進入同一治療領域，每家公司都越來越注重品牌建設、醫生互動計畫、拓展分銷網路以及製定針對特定治療領域的行銷策略，以求在競爭中脫穎而出。

例如，2025年12月，Cipla在印度推出了Yurpeak（tirzepatide），鞏固了在快速成長的代謝疾病領域的地位。此舉凸顯了製藥公司如何圍繞廣泛使用的分子建立獨特的品牌形象，以提高市場滲透率和患者忠誠度。

市場促進因素

對價格適中的品牌藥的需求日益成長

對價格合理的治療方案日益成長的需求仍然是主要的成長要素。病人和醫療專業人員都在尋求經濟有效的替代方案，以取代昂貴的品牌藥，同時又不影響治療的可靠性。

隨著慢性疾病負擔的加重，長期治療的需求日益成長，促使製藥公司將成熟藥物的非專利藥推向市場。2026年3月，Dr. Reddy's Laboratories在印度推出了用於治療第二型糖尿病的司Semaglutide注射劑學名藥Obeda，擴大了糖尿病患者獲得先進治療方案的途徑。

市場限制因素

非品牌學名藥之間的競爭非常激烈

儘管成長前景強勁，但來自低成本、無品牌學名藥的激烈競爭仍對市場擴張構成挑戰。由於多家製造商在同一治療領域競爭，價格壓力降低了盈利，限制了對促銷活動和產品系列擴張的投資。

在醫療保健系統優先考慮成本最低的藥品的成熟市場中，這項挑戰尤其突出。

市場機會

高附加價值藥品專利到期

重磅藥物專利到期為品牌非專利生產商帶來了重大機會。透過推出價格較低的成熟療法品牌學名藥，製藥公司既能確保更多患者獲得治療，又能維持商業性獲利能力。

例如，在專利到期後，Sun Pharma 於2026年 1月在印度獲得批准，可以生產和銷售名為「Noveltreat」的Semaglutide注射的學名藥。

市場挑戰

法規遵從性和生產品質

在多個監管轄區保持合規仍然是一項重大挑戰。公司必須遵守嚴格的生產標準、生物等效性要求、標籤法規和品管措施。

產品召回和生產相關問題會影響品牌聲譽並增加營運成本，因此合規是持續成功的關鍵因素。

細分分析

依治療領域

2025年，心血管疾病領域成為市場成長的主要驅動力。高血壓、心臟衰竭和冠狀動脈疾病等疾病需要長期治療，因此對價格適中的品牌藥有持續的需求。

受全球糖尿病盛行率不斷上升的推動，糖尿病治療領域預計將呈現最快的成長速度，在預測期內實現 8.10%的年複合成長率。

依給藥途徑

由於口服給藥方便、患者遵守用藥性高、生產成本低、商業性覆蓋率廣，到2025年，口服給藥領域佔據最大的市場佔有率。

預計到2034年，吸入劑市場將以 8.21%的年複合成長率成長。

依通路

到2025年，零售藥局憑藉其廣泛的分銷網路和高度的便利性佔據最大的市場佔有率。

受數位醫療保健的普及和電子商務滲透率的不斷提高的推動，線上藥房領域預計將以 11.99%的年複合成長率成長最快。

區域分析

北美洲

到2025年，北美市場規模達229.8億美元，引領全球品牌學名藥市場。高處方箋率、有利於學名藥的政策以及慢性病帶來的沉重負擔是推動該地區市場成長的主要因素。

預計到2026年，美國市場規模將達到 224.7億美元。

歐洲

受對經濟實惠的藥品需求不斷成長以及醫療保健成本控制措施的推動，預計到2026年，歐洲市場規模將達到 392.9億美元。

  • 英國市場（2026年）：57.1億美元
  • 德國市場（2026年）：59.1億美元

亞太地區

預計到2026年，亞太地區市場規模將達到981.4億美元，成為成長最快的區域市場之一。醫療服務可近性的提高、人口的成長以及醫師對品牌藥的偏好，都是推動市場擴張的主要因素。

  • 中國市場（2026年）：210.2億美元
  • 印度市場（2026年）：311.8億美元
  • 日本市場（2026年）：89.1億美元

拉丁美洲、中東和非洲

這些地區正經歷漸進但穩定的成長，這得益於醫療基礎設施的改善和獲得價格合理的藥品的機會增加。

  • 拉丁美洲市場（2026年）：283.5億美元
  • 海灣合作理事會市場（2026年）：52.4億美元
  • 南非市場（2026年）：34.4億美元

近期產業趨勢包括Semaglutide、Liraglutide、brivaracetam、硫酸沙丁胺醇吸入氣霧劑和Mercaptopurine口服懸浮液的核准上市，這反映了品牌非專利領域積極的創新和商業化。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 概述：2025年市場上的主要品牌學名藥
  • 主要地區和國家主要疾病的流行情況
  • 新產品發布：依主要公司分類
  • 主要產業趨勢（合併、收購、合作、新產品和服務的推出等）

第5章 2021-2034年全球品牌學名藥市場分析、洞察與預測

  • 市場分析、洞察與預測：依治療領域分類
    • 抗感染藥物
    • 心血管系統
    • 消化器官系統
    • 維生素、礦物質、營養補充劑
    • 中樞神經系統（CNS）
    • 呼吸系統
    • 抗糖尿病藥物
    • 皮膚科
    • 疼痛管理
    • 其他
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 腸外
    • 外用
    • 吸入
    • 其他
  • 市場分析、洞察與預測：依通路分類
    • 零售藥房
    • 醫院藥房
    • 網路藥房
    • 其他
  • 分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美品牌學名藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 2021-2034年歐洲品牌學名藥市場分析、洞察與預測

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太地區品牌學名藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章 拉丁美洲品牌學名藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 2021-2034年中東和非洲品牌學名藥市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Abbott
    • Sun Pharmaceutical Industries Limited
    • Dr. Reddy's Laboratories Limited
    • Cipla Limited
    • Lupin
    • Viatris Inc.
    • Sandoz AG
    • Hikma Pharmaceuticals PLC
    • Alkem Laboratories Limited
    • Zydus Lifesciences Limited
Product Code: FBI116042

Growth Factors of branded generics Market

The global branded generics market was valued at USD 204.31 billion in 2025 and is projected to grow from USD 218.02 billion in 2026 to USD 366.00 billion by 2034, registering a CAGR of 6.69% during the forecast period. The market is witnessing steady expansion as pharmaceutical companies increasingly introduce branded versions of off-patent medicines to improve product recognition, physician confidence, and patient acceptance. Branded generics provide a balance between affordability and trusted brand identity, making them particularly attractive in price-sensitive healthcare systems.

The rising prevalence of chronic diseases such as cardiovascular disorders, diabetes, respiratory diseases, and neurological conditions is fueling demand for cost-effective medications. Companies including Abbott, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Lupin Limited, and Hikma Pharmaceuticals PLC continue to strengthen their branded generic portfolios through product launches, regulatory approvals, and strategic collaborations.

Market Size and Forecast

  • 2025 Market Size: USD 204.31 Billion
  • 2026 Market Size: USD 218.02 Billion
  • 2034 Market Size: USD 366.00 Billion
  • CAGR (2026-2034): 6.69%

Key Market Trends

Increasing Competition Encouraging Brand Differentiation

One of the most significant trends shaping the branded generics market is the growing focus on product differentiation. As more manufacturers enter the same therapeutic categories, companies are increasingly relying on branding, physician engagement programs, distribution expansion, and therapy-specific marketing strategies to stand out.

For example, in December 2025, Cipla launched Yurpeak (tirzepatide) in India, strengthening its position in the growing metabolic disorders segment. Such developments highlight how pharmaceutical firms are creating distinct brand identities around widely used molecules to improve market penetration and patient loyalty.

Market Drivers

Rising Demand for Affordable Branded Medicines

The increasing demand for affordable treatment options remains the primary growth driver. Patients and healthcare providers are seeking cost-effective alternatives to expensive branded drugs without compromising treatment reliability.

The growing burden of chronic diseases has increased demand for long-term therapies, encouraging pharmaceutical companies to introduce branded generic versions of established medications. In March 2026, Dr. Reddy's Laboratories launched Obeda, a generic semaglutide injection for Type 2 diabetes in India, expanding access to advanced diabetes treatment.

Market Restraints

Intense Price Competition from Unbranded Generics

Despite strong growth prospects, intense competition from low-cost unbranded generic medicines continues to challenge market expansion. As multiple manufacturers compete within the same therapeutic categories, pricing pressure reduces profitability and limits investment in promotional activities and portfolio expansion.

This challenge is particularly evident in mature markets where healthcare systems prioritize the lowest-cost medicines available.

Market Opportunities

Patent Expiry of High-Value Drugs

The expiration of patents for blockbuster medicines is creating substantial opportunities for branded generic manufacturers. Pharmaceutical companies can launch lower-cost branded versions of proven therapies, enabling wider patient access while maintaining commercial viability.

For instance, Sun Pharma received approval in January 2026 to manufacture and market generic semaglutide injections in India under the brand name Noveltreat following patent expiration.

Market Challenges

Regulatory Compliance and Manufacturing Quality

Maintaining compliance across multiple regulatory jurisdictions remains a major challenge. Companies must adhere to strict manufacturing standards, bioequivalence requirements, labeling regulations, and quality-control measures.

Product recalls and manufacturing-related observations can impact brand reputation and increase operational costs, making compliance a critical factor for sustained success.

Segmentation Analysis

By Therapy Area

The cardiovascular diseases segment dominated the market in 2025. Conditions such as hypertension, heart failure, and coronary artery disease require long-term treatment, creating sustained demand for affordable branded medicines.

The anti-diabetic segment is expected to record the fastest growth, registering a CAGR of 8.10% during the forecast period due to increasing diabetes prevalence worldwide.

By Route of Administration

The oral segment held the largest market share in 2025 owing to ease of administration, better patient compliance, lower manufacturing costs, and broader commercial reach.

The inhalation segment is anticipated to grow at a CAGR of 8.21% through 2034.

By Distribution Channel

Retail pharmacies accounted for the largest market share in 2025 due to their extensive distribution networks and accessibility.

The online pharmacies segment is projected to witness the fastest expansion with a CAGR of 11.99%, supported by digital healthcare adoption and growing e-commerce penetration.

Regional Analysis

North America

North America dominated the global branded generics market in 2025 with a valuation of USD 22.98 billion. High prescription volumes, favorable generic drug policies, and a significant chronic disease burden support regional growth.

The U.S. market is projected to reach USD 22.47 billion in 2026.

Europe

Europe is expected to reach USD 39.29 billion in 2026, driven by increasing demand for cost-effective medicines and healthcare cost-containment initiatives.

  • U.K. Market (2026): USD 5.71 Billion
  • Germany Market (2026): USD 5.91 Billion

Asia Pacific

Asia Pacific is projected to reach USD 98.14 billion in 2026, making it one of the fastest-growing regional markets. Rising healthcare access, growing populations, and physician preference for branded medicines are supporting expansion.

  • China Market (2026): USD 21.02 Billion
  • India Market (2026): USD 31.18 Billion
  • Japan Market (2026): USD 8.91 Billion

Latin America and Middle East & Africa

These regions are witnessing moderate but steady growth due to improving healthcare infrastructure and increasing access to affordable medicines.

  • Latin America Market (2026): USD 28.35 Billion
  • GCC Market (2026): USD 5.24 Billion
  • South Africa Market (2026): USD 3.44 Billion

Competitive Landscape

The market remains highly consolidated, with major pharmaceutical companies focusing on product launches, partnerships, and geographic expansion strategies.

Leading companies include:

  • Abbott
  • Sun Pharmaceutical Industries Limited
  • Dr. Reddy's Laboratories Limited
  • Cipla Limited
  • Lupin Limited
  • Viatris Inc.
  • Sandoz AG
  • Hikma Pharmaceuticals PLC
  • Alkem Laboratories Limited
  • Zydus Lifesciences Limited

Recent industry developments include approvals and launches of semaglutide, liraglutide, brivaracetam, albuterol sulfate inhalation aerosol, and mercaptopurine oral suspension, reflecting strong innovation and commercialization activity within the branded generics sector.

Conclusion

The global branded generics market is poised for substantial growth, expanding from USD 204.31 billion in 2025 to USD 366.00 billion by 2034. Rising demand for affordable medicines, increasing chronic disease prevalence, patent expirations of high-value drugs, and strong product launch activity are driving market expansion. Although pricing pressure from unbranded generics and regulatory compliance requirements remain challenges, the market continues to benefit from expanding healthcare access, physician trust in branded products, and growing opportunities in chronic-care therapeutic segments worldwide.

Segmentation By Therapy Area, Route of Administration, Distribution Channel, and Region

By Therapy Area * Anti-infectives

  • Cardiovascular
  • Gastrointestinal
  • Vitamins, Minerals & Nutritional
  • CNS
  • Respiratory
  • Anti-diabetic
  • Dermatology
  • Pain Management
  • Others

By Route of Administration * Oral

  • Parenteral
  • Topical
  • Inhalation
  • Others

By Distribution Channel * Retail Pharmacies

  • Hospital Pharmacies
  • Online Pharmacies
  • Others

By Region * North America (By Therapy Area, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Therapy Area, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Therapy Area, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Therapy Area, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Therapy Area, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview: Key Branded Generics in the Market, 2025
  • 4.2. Prevalence of Key Diseases, By Key Regions/ Countries
  • 4.3. New Product Launches, By Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Branded Generics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 5.1.1. Anti-infectives
    • 5.1.2. Cardiovascular
    • 5.1.3. Gastrointestinal
    • 5.1.4. Vitamins, Minerals & Nutritional
    • 5.1.5. CNS
    • 5.1.6. Respiratory
    • 5.1.7. Anti-diabetic
    • 5.1.8. Dermatology
    • 5.1.9. Pain Management
    • 5.1.10. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
    • 5.2.3. Topical
    • 5.2.4. Inhalation
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Retail Pharmacies
    • 5.3.2. Hospital Pharmacies
    • 5.3.3. Online Pharmacies
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Branded Generics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 6.1.1. Anti-infectives
    • 6.1.2. Cardiovascular
    • 6.1.3. Gastrointestinal
    • 6.1.4. Vitamins, Minerals & Nutritional
    • 6.1.5. CNS
    • 6.1.6. Respiratory
    • 6.1.7. Anti-diabetic
    • 6.1.8. Dermatology
    • 6.1.9. Pain Management
    • 6.1.10. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
    • 6.2.3. Topical
    • 6.2.4. Inhalation
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Retail Pharmacies
    • 6.3.2. Hospital Pharmacies
    • 6.3.3. Online Pharmacies
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Branded Generics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 7.1.1. Anti-infectives
    • 7.1.2. Cardiovascular
    • 7.1.3. Gastrointestinal
    • 7.1.4. Vitamins, Minerals & Nutritional
    • 7.1.5. CNS
    • 7.1.6. Respiratory
    • 7.1.7. Anti-diabetic
    • 7.1.8. Dermatology
    • 7.1.9. Pain Management
    • 7.1.10. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
    • 7.2.3. Topical
    • 7.2.4. Inhalation
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Retail Pharmacies
    • 7.3.2. Hospital Pharmacies
    • 7.3.3. Online Pharmacies
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Branded Generics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 8.1.1. Anti-infectives
    • 8.1.2. Cardiovascular
    • 8.1.3. Gastrointestinal
    • 8.1.4. Vitamins, Minerals & Nutritional
    • 8.1.5. CNS
    • 8.1.6. Respiratory
    • 8.1.7. Anti-diabetic
    • 8.1.8. Dermatology
    • 8.1.9. Pain Management
    • 8.1.10. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
    • 8.2.3. Topical
    • 8.2.4. Inhalation
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Retail Pharmacies
    • 8.3.2. Hospital Pharmacies
    • 8.3.3. Online Pharmacies
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Southeast Asia
    • 8.4.5. Australia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Branded Generics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 9.1.1. Anti-infectives
    • 9.1.2. Cardiovascular
    • 9.1.3. Gastrointestinal
    • 9.1.4. Vitamins, Minerals & Nutritional
    • 9.1.5. CNS
    • 9.1.6. Respiratory
    • 9.1.7. Anti-diabetic
    • 9.1.8. Dermatology
    • 9.1.9. Pain Management
    • 9.1.10. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
    • 9.2.3. Topical
    • 9.2.4. Inhalation
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Retail Pharmacies
    • 9.3.2. Hospital Pharmacies
    • 9.3.3. Online Pharmacies
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Branded Generics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 10.1.1. Anti-infectives
    • 10.1.2. Cardiovascular
    • 10.1.3. Gastrointestinal
    • 10.1.4. Vitamins, Minerals & Nutritional
    • 10.1.5. CNS
    • 10.1.6. Respiratory
    • 10.1.7. Anti-diabetic
    • 10.1.8. Dermatology
    • 10.1.9. Pain Management
    • 10.1.10. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
    • 10.2.3. Topical
    • 10.2.4. Inhalation
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Retail Pharmacies
    • 10.3.2. Hospital Pharmacies
    • 10.3.3. Online Pharmacies
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Abbott
    • 11.2.2. Sun Pharmaceutical Industries Limited
    • 11.2.3. Dr. Reddy's Laboratories Limited
    • 11.2.4. Cipla Limited
    • 11.2.5. Lupin
    • 11.2.6. Viatris Inc.
    • 11.2.7. Sandoz AG
    • 11.2.8. Hikma Pharmaceuticals PLC
    • 11.2.9. Alkem Laboratories Limited
    • 11.2.10. Zydus Lifesciences Limited

List of Tables

  • Figure 1: Global Branded Generics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Branded Generics Market Value Share (%), by Therapy Area, 2025 & 2034
  • Figure 3: Global Branded Generics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Branded Generics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Branded Generics Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Branded Generics Market Value (USD billion), by Therapy Area, 2025 & 2034
  • Figure 7: North America Branded Generics Market Value Share (%), by Therapy Area, 2025
  • Figure 8: North America Branded Generics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America Branded Generics Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Branded Generics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Branded Generics Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Branded Generics Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Branded Generics Market Value Share (%), by Country, 2025
  • Figure 14: Europe Branded Generics Market Value (USD billion), by Therapy Area, 2025 & 2034
  • Figure 15: Europe Branded Generics Market Value Share (%), by Therapy Area, 2025
  • Figure 16: Europe Branded Generics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Branded Generics Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Branded Generics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Branded Generics Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Branded Generics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Branded Generics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Branded Generics Market Value (USD billion), by Therapy Area, 2025 & 2034
  • Figure 23: Asia Pacific Branded Generics Market Value Share (%), by Therapy Area, 2025
  • Figure 24: Asia Pacific Branded Generics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Branded Generics Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Branded Generics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Branded Generics Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Branded Generics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Branded Generics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Branded Generics Market Value (USD billion), by Therapy Area, 2025 & 2034
  • Figure 31: Latin America Branded Generics Market Value Share (%), by Therapy Area, 2025
  • Figure 32: Latin America Branded Generics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America Branded Generics Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America Branded Generics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Branded Generics Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Branded Generics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Branded Generics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Branded Generics Market Value (USD billion), by Therapy Area, 2025 & 2034
  • Figure 39: Middle East & Africa Branded Generics Market Value Share (%), by Therapy Area, 2025
  • Figure 40: Middle East & Africa Branded Generics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa Branded Generics Market Value Share (%), by Route of Administration, 2025
  • Figure 42: Middle East & Africa Branded Generics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Branded Generics Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Branded Generics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Branded Generics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Branded Generics Market Share (%), by Company, 2025